Sanofi unveils Phase 3 trial results of isatuximab combination therapy
Category: #health  | By Mateen Dalal  | Date: 2019-06-04 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Sanofi unveils Phase 3 trial results of isatuximab combination therapy

The French multinational pharmaceutical company Sanofi has reportedly announced crucial Phase 3 ICARIA-MM trial results which revealed that isatuximab aided with dexamethasone and pomalidomide (isatuximab combination therapy) has shown statistically substantial improvements compared to pomalidomide and dexamethasone (pom-dex) alone in patients enduring relapsed/refractory multiple myeloma (RRMM). The results were recently presented at annual meeting in Chicago at the 2019 American Society of Clinical Oncology (ASCO).

Paul Richardson, MD, clinical program leader, principal investigator, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, reportedly stated that Isatuximab added to pomalidomide and dexamethasone has resulted in remarkable 40 percent decrease in the risk of progression or demise in comparison with pomalidomide and dexamethasone alone. The result is significant because the study included a particularly relapsed, refractory and difficult-to-treat patient population, which was highly reflecting real-world practice, he further added.

Reportedly, Isatuximab combination therapy has shown a statistically significant improvement in progression free survival, and the median progression free survival was longer in the isatuximab combination therapy arm than pom-dex alone.

Apparently, ICARIA-MM is a crucial Phase 3 open-label, randomized, multi-center study assessing isatuximab combined with pom-dex against pom-dex alone in patients enduring RRMM. Around 307 patients suffering from RRMM have been enrolled in the study at around 96 centers in 24 nations. Overall, patients were given a median of 3 prior lines of anti-myeloma treatments which includes minimum 2 sequential cycles of a proteasome inhibitor and lenalidomide given alone or in combination.

During the study, Isatuximab was dispensed via an intravenous infusion at a dose of 10mg/kg once weekly for 4 weeks and further every other week for 28-day cycles combined with pom-dex standard doses for the period of therapy.

For the record, Isatuximab is an experimental monoclonal antibody which targets a particular epitope on the CD38 receptor of a plasma cell.

 

Source link: http://hugin.info/152918/R/2245494/886977.pdf

https://www.finanznachrichten.de/nachrichten-2019-06/46854851-sanofi-phase-3-trial-of-isatuximab-combination-therapy-showed-40-reduction-in-the-risk-of-disease-progression-or-death-for-patients-with-relapsed-re-399.htm

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Intellect chooses IHH Healthcare to devise mental health programs

Intellect chooses IHH Healthcare to devise mental health programs

By Mateen Dalal

Intellect, a leading mental health platform located in Singapore, has reportedly announced a partnership with IHH Healthcare, which is Asia’s largest private healthcare group. The main objective of the partnership is to introduce and customize ...

Dyson compensates employees with onetime payment in absence of bonus

Dyson compensates employees with onetime payment in absence of bonus

By Mateen Dalal

Dyson, a British company renowned for its innovative vacuum cleaners, hair dryers and other products, is reportedly offering a majority of the staff at its Singapore headquarters a one-time payment, in recognition of their exceptional contribution. ...

Sapeon pursues new funding round to achieve $400 Mn valuation

Sapeon pursues new funding round to achieve $400 Mn valuation

By Mateen Dalal

Sapeon, a South Korean start-up focusing on the design of artificial intelligence semiconductors for data centers is seeking a funding round to bring its valuation to USD 400 million. Sapeon has the strong support of industry giants like SK Teleco...